As the first treatment cleared by the FDA for Demodex blepharitis, an eye disease estimated to affect 25 million people in the U.S. alone, Tarsus Pharmaceuticals’ Xdemvy is pitting its might ...
starting with eye care, today announced the launch of a new direct-to-consumer TV campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%, the first and only FDA approved treatment for ...